AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$PGNY

Progyny Q3 Earnings Call Highlights

Progyny (PGNY) reported Q3 earnings, highlighting a 130 basis point gross margin expansion and $56M in operating cash flow. CEO Anevski noted high client attach rates for Progyny Rx and expects 3M lives to access expanded products by 2027. The company repurchased 3M shares for $83M and plans to taper investments in 2027.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 5:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 5:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Progyny Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PGNYBullishHigh
01

Why it matters

The earnings beat and buyback provide a fresh catalyst that could lift the stock, though guidance for 2027 is pending.

02

Market read

First report of Q3 financials and a $83M buyback, offering a clear short‑term trading opportunity.

03

What to watch

Potential slowdown in public‑sector utilization and lack of new guidance may temper upside.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

Progyny is a benefits‑management firm focused on fertility and family‑building services, reporting Q3 results and a share repurchase program.

Company-level read

Ticker impact

$PGNYBullishHigh confidence
Context

Q3 earnings disclosed $56M operating cash flow, margin expansion and a $83M share repurchase, the first public release of these figures.

Expected impact

upward pressure as investors price in stronger cash flow and the $83M repurchase.

Evidence & confidence

Margin expansion, cash generation and a large buyback tranche are fresh, material data that can move the share price in the near term.

Market effects

Sector

Fertility benefits sector may see increased investor interest from the earnings beat.

Regional

U.S. health‑benefits niche gains modest attention.

Global

Limited to U.S. listed health‑benefits companies.

Counterpoint

What could challenge this read

Buyback could be a short‑term catalyst but underlying growth may still be modest.

Key entities

  • CEO
    Josh Anevski

    Provided commentary on Rx attach rates and pipeline.

  • CFO
    John Livingston

    Discussed margins, cash flow and share repurchase details.

Read at source← All news

StoryProgyny reports third-quarter revenue growth and raises full-year guidance

Also covered by

3 outlets

Related articles

$PGNYMed

Progyny (PGNY) Q3 2026 Earnings Call Transcript

Progyny (PGNY) reported record revenue and profitability for Q3 2026, with strong cash flow used for growth and share repurchases. The company added 1.3M new covered lives and 85 new clients, raising full-year guidance. Management highlighted strong demand for family building and women's health benefits, diverse client base, and market differentiation. Retention was near 100%, with 20% of clients expanding services. Progyny Select, a new offering, is expected to contribute to long-term growth.

finance.yahoo.com
$PGNYMedAI 8/10

Progyny 3Q 2026: Revenue $341.25M, EPS $0.32 — 10-Q Summary

Progyny reported 3Q 2026 revenue of $341.25M, up 8.9% YoY, and net income of $26.25M, up 89.4% YoY. Growth was driven by increased client and covered-life counts, improving gross margin to 24.5%. Fertility benefits and Progyny Rx revenue rose 11% and 6%, respectively. The company served 607 clients and 7.155M members as of September 30, 2026.

tradingview.com